GI MAP Stool Test Review: Diagnostic Solutions

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

The GI-MAP (Microbial Assay Plus) is a comprehensive stool test that uses quantitative polymerase chain reaction (qPCR) technology.
It detects parasites, bacteria, H. pylori, fungi, and more by targeting the specific DNA of the organisms tested.
Diagnostic Solutions Laboratory reports a current GI-MAP turnaround time of 7–10 business days.
New for 2025, the GI-MAP will include Bile Acids and Short Chain Fatty Acids Testing.

The GI-MAP (Microbial Assay Plus) is a comprehensive stool test offered by Diagnostic Solutions Laboratory that provides detailed insights into gut health. This advanced test uses quantitative polymerase chain reaction (qPCR) technology to identify a wide range of microorganisms in the digestive tract, including parasites, bacteria, H. pylori, and fungi. By targeting the specific DNA of these organisms, the GI-MAP offers a precise and quantitative assessment of the gut microbiome. Practitioners use this information to understand the root causes of patient symptoms, moving beyond superficial diagnoses to create personalized treatment plans. The test is known for its efficiency, with Diagnostic Solutions Laboratory reporting a current turnaround time of 7–10 business days for results. This allows for timely intervention and monitoring of treatment efficacy. Looking ahead, the GI-MAP is set to expand its capabilities in 2025 with the addition of Bile Acids and Short Chain Fatty Acids testing, further enhancing its ability to provide a holistic picture of gut function.

What is the GI-MAP Stool Test?

The GI-MAP (Microbial Assay Plus) is a comprehensive stool test designed to analyze the microbial composition of the gastrointestinal tract. This test is a product of Diagnostic Solutions Laboratory, a company dedicated to delivering innovative and accurate diagnostic testing. Unlike traditional culture-based methods, the GI-MAP employs advanced quantitative polymerase chain reaction (qPCR) technology to identify various microorganisms. This technology allows for the direct detection of specific DNA from organisms present in the stool sample, providing a highly sensitive and specific assessment of the gut microbiome. The GI-MAP aims to give healthcare providers a detailed understanding of a patient's gut health, which is crucial for addressing complex health issues.

The Foundation of GI-MAP Testing

The foundation of the GI-MAP test lies in its ability to analyze the complex ecosystem within the gut. This ecosystem includes a wide array of bacteria, fungi, parasites, and viruses, all of which play a role in digestive health and overall well-being. When this delicate balance is disrupted, it can lead to various symptoms and chronic conditions. The GI-MAP helps pinpoint these imbalances by providing quantitative data on the presence and abundance of specific microbes. This quantitative aspect is particularly valuable, as it allows practitioners to track changes over time and assess the effectiveness of interventions. The test is often utilized by functional medicine practitioners who seek to understand the underlying causes of health problems rather than just managing symptoms. Its comprehensive nature makes it a cornerstone for personalized medicine approaches in gastrointestinal health.

Why Comprehensive Testing Matters

Comprehensive testing, such as that provided by the GI-MAP, is essential because no two people are alike, even if they present with similar symptoms. The root causes of digestive issues can vary widely from one individual to another. Diagnostic testing, therefore, becomes crucial for tailoring health interventions that are specifically designed for each patient. Functional medicine, with its holistic approach, relies on tests like the GI-MAP to delve deeper into the problem. Without the right kind of testing, it can be difficult to determine the exact nature of gut imbalances, as symptoms often mimic other conditions. The GI-MAP sheds light on what is truly happening in the body, offering insights that traditional tests might miss. This allows for more targeted and effective treatment strategies.

The Role of Diagnostic Solutions Laboratory

Diagnostic Solutions Laboratory is the developer and provider of the GI-MAP test. Their mission is clear: "to deliver innovative, accurate and clinically relevant diagnostic testing in a timely and cost-effective manner." This commitment guides their approach to developing and refining tests like the GI-MAP. The laboratory emphasizes research, technology, and results, ensuring that the tests they offer are grounded in scientific rigor and provide actionable information. Their dedication to advanced methodologies ensures that practitioners receive reliable data to inform their clinical decisions. The GI-MAP is an example of their pursuit of unparalleled DNA-based stool testing, setting a high standard for microbial analysis in the functional medicine space.

How Does GI-MAP Technology Work?

The GI-MAP (Microbial Assay Plus) test operates on the principle of quantitative polymerase chain reaction (qPCR) technology. This advanced molecular method is highly effective at detecting and quantifying specific DNA sequences from microorganisms present in a stool sample. The core of qPCR technology involves amplifying small amounts of DNA, making it detectable and measurable. This allows the test to identify not only the presence of various microbes but also their relative abundance within the gut environment. By focusing on the unique genetic signatures of different organisms, qPCR offers a level of specificity and sensitivity that is crucial for accurate microbial profiling.

Understanding Quantitative Polymerase Chain Reaction (qPCR)

Quantitative polymerase chain reaction, or qPCR, is a laboratory technique that combines DNA amplification with fluorescence detection. Here's a simplified breakdown of how it works in the context of the GI-MAP: First, DNA is extracted from the stool sample. Then, specific "primers" are added, which are short DNA sequences designed to bind only to the DNA of target organisms (e.g., specific bacteria, parasites, or fungi). A fluorescent dye is also included in the reaction mixture. As the target DNA is amplified through cycles, the fluorescent signal increases, allowing the lab equipment to measure the amount of DNA present. The "quantitative" aspect means that the test can determine how much of a particular organism's DNA is in the sample, not just whether it is present or absent. This provides a numerical value for each detected microbe, which is incredibly useful for understanding microbial load and identifying potential overgrowths or deficiencies.

Targeting Specific Microbial DNA

The precision of the GI-MAP test comes from its ability to target the specific DNA of organisms. Each type of bacteria, parasite, or fungus has a unique genetic fingerprint. The qPCR primers are designed to recognize and bind exclusively to these unique sequences. This specificity ensures that the test accurately identifies the intended organisms without cross-reactivity with other microbes. For example, the GI-MAP can differentiate between various species of H. pylori and even detect specific virulence factors associated with this bacterium. This detailed level of identification is a significant advantage over older methods, which might only identify broader categories of microbes or struggle with differentiating closely related species. The ability to target specific DNA makes the GI-MAP a highly reliable tool for assessing microbial communities in the gut.

Advantages Over Traditional Testing Methods

The qPCR technology used in the GI-MAP offers several advantages over traditional stool testing methods. Older methods, such as culture-based tests, rely on growing microorganisms in a lab. However, many gut microbes are anaerobic and difficult or impossible to culture in a laboratory setting, leading to an incomplete picture of the microbiome. Culture tests also often struggle with quantifying organisms accurately. In contrast, qPCR directly detects DNA, meaning it can identify both culturable and non-culturable organisms. This provides a more comprehensive and accurate representation of the gut's microbial landscape. Additionally, qPCR is generally faster and less prone to human error than culture methods, contributing to the reported 7–10 business days turnaround time for GI-MAP results from Diagnostic Solutions Laboratory. The speed and accuracy of qPCR make it a preferred method for detailed gut microbiome analysis in functional medicine. Diagnostic Solutions Laboratory highlights that their technology provides superior insight into gut health.

What Does the GI-MAP Test For?

The GI-MAP (Microbial Assay Plus) test offers a broad spectrum of insights into the gut microbiome, identifying a wide array of microorganisms and markers crucial for understanding digestive health. This comprehensive test goes beyond basic pathogen screening to provide a detailed profile of the gut ecosystem. It assesses various categories of microbes, including pathogenic bacteria, commensal bacteria, opportunistic bacteria, parasites, fungi, and specific virulence factors related to H. pylori. The goal is to uncover imbalances, infections, and other factors that may contribute to gastrointestinal symptoms and systemic health issues. By detecting the specific DNA of these organisms, the GI-MAP provides quantitative data that helps practitioners identify root causes and develop targeted treatment strategies.

Detection of Pathogenic Bacteria and H. pylori

One of the primary functions of the GI-MAP is to detect pathogenic bacteria that can cause infections and inflammation in the gut. These include well-known culprits such as Clostridium difficile, E. coli (various pathogenic strains), Salmonella, Shigella, and Campylobacter. Identifying these pathogens is critical for treating acute and chronic digestive problems. Beyond general pathogenic bacteria, the GI-MAP also specifically assesses H. pylori, a bacterium commonly associated with gastritis, ulcers, and an increased risk of gastric cancer. Crucially, the test also screens for H. pylori virulence factors. These are specific genes (cagA and vacA) that indicate a more aggressive or problematic strain of H. pylori, providing valuable information for clinical decision-making. The presence and type of H. pylori can significantly impact treatment approaches, making this detailed analysis highly relevant.

Assessment of Commensal and Opportunistic Bacteria

The GI-MAP provides a detailed look at both commensal (beneficial) and opportunistic bacteria. Commensal bacteria are essential for a healthy gut, playing roles in nutrient absorption, vitamin production, immune regulation, and protection against pathogens. The test quantifies key beneficial bacteria like Bifidobacterium and Lactobacillus species, helping to identify deficiencies that might impact gut function. On the other hand, opportunistic bacteria are those that can cause problems if their numbers become too high or if the gut environment is compromised. These might include certain species of Klebsiella, Pseudomonas, or Citrobacter. While normally present in small amounts, an overgrowth of these bacteria can contribute to inflammation, dysbiosis, and symptoms like bloating, gas, and abdominal pain. Understanding the balance between beneficial and opportunistic microbes is key to restoring gut health.

Screening for Parasites, Yeast, and Fungi

Parasitic infections can be a significant cause of chronic digestive issues, often going undiagnosed by less comprehensive tests. The GI-MAP screens for a wide range of parasites, including protozoa suchzoa as Giardia lamblia, Cryptosporidium, Entamoeba histolytica, and Blastocystis hominis. It also looks for various worms (helminths), providing a thorough assessment for parasitic burdens. In addition to parasites, the test identifies yeast and fungi, with a particular focus on Candida species. Candida overgrowth is a common issue in functional medicine, linked to various symptoms beyond the gut, including fatigue, brain fog, and skin issues. By quantifying the presence of these organisms, the GI-MAP helps practitioners determine if yeast or fungal overgrowth is contributing to a patient's health concerns, allowing for targeted antifungal or anti-parasitic treatments. The GI-MAP Interpretive Guide offers detailed explanations of all markers tested.

Additional Biomarkers for Comprehensive Gut Health

Beyond microbial detection, the GI-MAP also incorporates several other biomarkers that provide a more complete picture of gut health. These markers can indicate inflammation, immune function, and digestive efficiency. For instance, markers of intestinal inflammation, such as calprotectin, can help identify inflammatory bowel disease (IBD) or other inflammatory conditions. Elastase-1 assesses pancreatic enzyme function, indicating whether the body is producing enough enzymes to properly digest food. Zonulin, a marker of intestinal permeability (leaky gut), can reveal issues with the gut barrier. Additionally, beta-glucuronidase levels can provide insight into detoxification pathways. By combining microbial analysis with these functional markers, the GI-MAP offers a holistic assessment that guides practitioners in developing comprehensive and personalized treatment plans for their patients. This multi-faceted approach ensures that various aspects of gut health are considered.

What New Features Are Coming to GI-MAP in 2025?

Diagnostic Solutions Laboratory is continuously enhancing the GI-MAP (Microbial Assay Plus) test to provide even more comprehensive insights into gut health. For 2025, the GI-MAP is set to introduce significant new features, specifically the inclusion of Bile Acids and Short Chain Fatty Acids (SCFAs) testing. These additions represent a substantial expansion of the test's capabilities, moving beyond microbial identification to incorporate key functional markers related to digestion, metabolism, and overall gut function. These new features will allow practitioners to gain a deeper understanding of how the gut is performing its crucial roles, further supporting the development of personalized health interventions.

The Addition of Bile Acids Testing

Starting in 2025, the GI-MAP will incorporate testing for Bile Acids. Bile acids are crucial molecules produced by the liver and stored in the gallbladder, playing a vital role in the digestion and absorption of fats and fat-soluble vitamins. They also act as signaling molecules, influencing gut motility, glucose metabolism, and immune responses. Imbalances in bile acid metabolism can contribute to various digestive issues, including malabsorption, dysbiosis, and even systemic problems. For example, altered bile acid profiles can impact the growth of certain gut bacteria, either positively or negatively. By including bile acid testing, the GI-MAP will provide practitioners with insights into fat digestion and absorption, as well as potential disruptions in the enterohepatic circulation of bile acids. This information can help identify issues such as small intestinal bacterial overgrowth (SIBO), bile acid malabsorption, or liver and gallbladder dysfunction that might be affecting gut health. The addition of this marker will offer a more complete picture of digestive physiology.

Inclusion of Short Chain Fatty Acids (SCFAs) Testing

Also new for 2025, the GI-MAP will feature testing for Short Chain Fatty Acids (SCFAs). SCFAs, such as butyrate, acetate, and propionate, are metabolic byproducts primarily produced when beneficial gut bacteria ferment dietary fiber in the colon. These compounds are critical for gut health and have far-reaching effects on systemic health. Butyrate, for instance, is the primary fuel source for colonocytes (cells lining the colon) and plays a significant role in maintaining gut barrier integrity and reducing inflammation. SCFAs also influence immune function, blood sugar regulation, and even brain health. Low levels of SCFAs can indicate a lack of beneficial fiber-fermenting bacteria, insufficient dietary fiber intake, or an imbalanced gut microbiome. Conversely, certain patterns of SCFAs might point to specific types of dysbiosis. By providing quantitative data on SCFAs, the GI-MAP will enable practitioners to assess the functional output of the gut microbiome, offering direct insights into microbial metabolic activity and its impact on host health. This will help tailor dietary and supplemental strategies to support a healthy gut environment.

Enhanced Insights for Comprehensive Gut Function

These new additions—Bile Acids and Short Chain Fatty Acids testing—will significantly enhance the GI-MAP's ability to provide comprehensive insights into gut function. Previously, the test primarily focused on identifying the presence and quantity of various microorganisms. With the inclusion of these metabolic markers, the GI-MAP will now offer a more dynamic view, showing not only who is in the gut but also what they are doing and how the gut is performing its digestive and metabolic roles. This integrated approach allows for a more nuanced understanding of complex gastrointestinal conditions. For example, a practitioner might identify an imbalance in gut bacteria (via qPCR) and then correlate it with altered SCFA levels, confirming a functional impact. Similarly, issues with fat digestion indicated by bile acid levels can be linked to specific microbial patterns. These additions provide more comprehensive insights into gut function, allowing for even more precise and personalized interventions. Rupa Health, which offers the GI-MAP, notes that such detailed testing is critical for functional medicine practitioners. Rupa Health's GI-MAP overview emphasizes the test's comprehensive nature.

How Long Does It Take to Get GI-MAP Results?

Getting timely results from diagnostic tests is crucial for both practitioners and patients, as it allows for prompt intervention and the development of effective treatment plans. Diagnostic Solutions Laboratory, the provider of the GI-MAP (Microbial Assay Plus) test, understands this need for efficiency. They have established a clear turnaround time for processing and delivering GI-MAP results, ensuring that healthcare providers can access vital information without undue delay. This commitment to timely service is part of their broader mission to deliver innovative, accurate, and clinically relevant diagnostic testing in a cost-effective manner.

Current Turnaround Time for GI-MAP Results

Diagnostic Solutions Laboratory currently reports a GI-MAP turnaround time of 7–10 business days. This timeframe begins once the laboratory receives the patient's sample. The process involves several steps, including sample registration, DNA extraction, quantitative polymerase chain reaction (qPCR) analysis for each target organism, data processing, and final report generation. Despite the complexity of the qPCR technology and the extensive list of markers analyzed, the laboratory strives to maintain this efficient processing schedule. This relatively quick turnaround allows practitioners to integrate the GI-MAP results into their patient consultations and treatment planning without significant delays. Knowing the expected timeframe helps manage patient expectations and facilitates the overall flow of care in a functional medicine practice.

Importance of Timely Results for Patient Care

Timely results from the GI-MAP test are critically important for effective patient care in functional medicine. When a patient is experiencing gastrointestinal symptoms or chronic health issues, waiting an extended period for diagnostic information can delay the start of appropriate treatment. A 7–10 business day turnaround time means that practitioners can quickly identify the specific microbial imbalances, pathogens, or functional markers contributing to a patient's condition. This rapid insight enables them to:

Formulate Personalized Treatment Plans: With concrete data on specific bacteria, parasites, fungi, and other markers, practitioners can design highly targeted protocols, including dietary changes, supplements, or antimicrobial therapies, rather than relying on broad-spectrum or trial-and-error approaches.
Monitor Treatment Efficacy: For follow-up testing, a consistent and relatively fast turnaround time allows practitioners to assess the impact of interventions in a reasonable timeframe. This helps determine if the chosen treatments are effectively shifting the gut microbiome and improving patient health.
Reduce Patient Anxiety: Patients often feel anxious when dealing with persistent health issues. Receiving results within a predictable and relatively short period can alleviate some of this stress and empower them to actively participate in their healing journey.

Diagnostic Solutions Laboratory's commitment to delivering results within 7–10 business days helps facilitate a proactive and responsive approach to gut health management. This efficiency supports the practitioner's ability to provide the best possible care, aligning with the core principles of functional medicine.

Streamlining the Diagnostic Process

The efficient turnaround time for GI-MAP results also helps streamline the broader diagnostic process within functional medicine practices. By having a reliable expectation for when results will be available, clinics can better schedule follow-up appointments and allocate resources. This predictability is especially valuable in practices that manage a large volume of patients with complex conditions, where multiple tests might be ordered over time. The ability to quickly process and deliver results for a comprehensive test like the GI-MAP underscores Diagnostic Solutions Laboratory's dedication to supporting healthcare providers. Their focus on "Research. Technology. Results." ensures that the tools they provide are not only scientifically sound but also practical for real-world clinical application. This makes the GI-MAP a highly valued diagnostic tool for many practitioners seeking to optimize gut health for their patients.

Why is Gut Microbiome Profiling Important for Health?

Gut microbiome profiling, particularly through advanced tests like the GI-MAP, is increasingly recognized as a cornerstone of comprehensive health assessment in functional medicine. The human gut harbors trillions of microorganisms that collectively form the gut microbiome, an intricate ecosystem with profound effects on virtually every aspect of health. Understanding the composition and function of this microbiome is critical because it plays a central role in digestion, nutrient absorption, immune system regulation, detoxification, and even neurological function. When this delicate balance is disrupted, known as dysbiosis, it can contribute to a wide range of symptoms and chronic diseases, both within and outside the digestive tract.

Identifying Root Causes of Health Issues

Functional profiling of the GI tract and microbiome is crucial because it helps identify the root causes of symptoms rather than just treating their manifestations. Many common health complaints, such as fatigue, skin problems, mood disorders, autoimmune conditions, and chronic pain, have been linked to imbalances in the gut. For instance, an overgrowth of certain opportunistic bacteria, a deficiency in beneficial microbes, or the presence of specific parasites or fungi detected by the GI-MAP can all be underlying drivers of systemic inflammation or nutrient malabsorption. Without this detailed microbial profile, practitioners might only address symptoms, leading to temporary relief rather than lasting health improvements. By pinpointing the specific microbial culprits or imbalances, functional medicine practitioners can develop highly targeted interventions that address the fundamental issues, leading to more effective and sustainable outcomes.

Informing Tailored Health Interventions

No two people are alike, and even if two family members have similar symptoms, the root causes can vary widely. This individuality underscores why diagnostic testing is so essential to tailor health interventions that work for each individual. The detailed data provided by gut microbiome profiling allows practitioners to move beyond a "one-size-fits-all" approach. For example, if the GI-MAP reveals a deficiency in specific beneficial bacteria, a practitioner might recommend targeted probiotics or prebiotics. If pathogenic bacteria or parasites are identified, specific antimicrobial herbs or pharmaceuticals can be prescribed. If inflammation markers are elevated, dietary changes and anti-inflammatory supplements can be introduced. This personalized approach, informed by concrete data from tests like the GI-MAP, significantly increases the likelihood of successful treatment. It ensures that interventions are precisely matched to the patient's unique biological needs, optimizing their journey towards better health.

The Gut-Brain Axis and Systemic Health

The importance of the gut microbiome extends far beyond the digestive system itself, influencing systemic health through complex interactions, most notably via the gut-brain axis. The gut and brain communicate constantly through neural, hormonal, and immune pathways. An imbalanced gut microbiome can affect neurotransmitter production, increase systemic inflammation, and alter gut permeability, all of which can impact brain function, mood, and cognitive health. Conditions like anxiety, depression, and even neurodegenerative disorders are increasingly being linked to gut dysbiosis. Furthermore, the gut microbiome plays a critical role in immune system development and function. An unhealthy gut can lead to immune dysregulation, contributing to allergies, autoimmune diseases, and increased susceptibility to infections. By providing a comprehensive profile of the gut microbiome, the GI-MAP offers crucial insights into these systemic connections, enabling practitioners to address not only digestive complaints but also a wide array of chronic health conditions by targeting the gut. Diagnostic Solutions Laboratory emphasizes the importance of GI and microbiome functional profiling for optimizing overall health.

Diagnostic Solutions Laboratory's Mission

The significance of comprehensive gut microbiome profiling is central to the mission of Diagnostic Solutions Laboratory. They are committed "to deliver innovative, accurate and clinically relevant diagnostic testing in a timely and cost-effective manner." This mission drives their development of tests like the GI-MAP, which uses advanced qPCR technology to provide unparalleled DNA-based stool testing. Their focus on research, technology, and results ensures that healthcare providers have access to the most reliable and insightful tools for assessing gut health. By offering detailed and actionable data, Diagnostic Solutions Laboratory empowers practitioners to delve into the root causes of disease, facilitate personalized treatment plans, and ultimately improve patient outcomes. The continuous evolution of the GI-MAP, including upcoming additions like Bile Acids and Short Chain Fatty Acids testing in 2025, reflects their dedication to advancing the field of functional diagnostics and supporting optimal health through a deeper understanding of the gut microbiome.

Frequently Asked Questions

What is the primary technology used in the GI-MAP test?

The GI-MAP (Microbial Assay Plus) test primarily uses quantitative polymerase chain reaction (qPCR) technology. This advanced method detects and quantifies the specific DNA of various microorganisms present in a stool sample. By amplifying and measuring unique genetic sequences, qPCR provides a highly sensitive and accurate assessment of the gut microbiome, including bacteria, parasites, and fungi. This technology allows for precise identification and quantification, which is superior to traditional culture-based methods.

What types of organisms can the GI-MAP detect?

The GI-MAP test is comprehensive and can detect a wide range of organisms. This includes pathogenic bacteria like Clostridium difficile and Salmonella, as well as H. pylori and its virulence factors. It also assesses beneficial commensal bacteria (e.g., Bifidobacterium, Lactobacillus), opportunistic bacteria (e.g., Klebsiella, Pseudomonas), parasites (e.g., Giardia, Cryptosporidium), and various yeast and fungi, such as Candida species. The test targets the specific DNA of these organisms for precise identification.

How long does it typically take to receive GI-MAP results?

Diagnostic Solutions Laboratory reports a current GI-MAP turnaround time of 7–10 business days. This timeframe begins once the laboratory receives the patient's sample. This relatively fast processing time ensures that practitioners can quickly access the detailed microbial and functional insights provided by the test. Timely results are crucial for developing and adjusting personalized treatment plans for patients with gastrointestinal issues.

Will the GI-MAP test include new markers in 2025?

Yes, the GI-MAP test is set to include new markers in 2025. Diagnostic Solutions Laboratory announced that new additions will feature Bile Acids and Short Chain Fatty Acids (SCFAs) testing. These new markers will provide further insights into digestive function, fat absorption, and the metabolic activity of the gut microbiome. The expanded panel will offer an even more comprehensive view of gut health.

Where can I find an interpretive guide for the GI-MAP test?

An interpretive guide for the GI-MAP test is available directly from Diagnostic Solutions Laboratory. This guide provides detailed explanations of all the markers tested, what the results mean, and how to interpret them in a clinical context. You can find this valuable resource at https://www.diagnosticsolutionslab.com/assets/documents/gi-map-interpretive-guide.pdf.